Search Results:

13th March, 2017

Designing a HIV immunogen capable of eliciting broad antibody responses has been a challenge in the field. The highest efficacy in an HIV vaccine trial was 31% which is not enough to protect the majority of vaccinees.

A 31 year old caucasian male presented to the HIV clinic complaining of recent onset of fever, vomiting, joint pain, muscle aches, sore throat and a fine red rash on his face and arms. All symptoms had worsened since they first started 2 days ago and seemed to be aggravated shortly…